ArticleEULAR rheumatology open2025
A case of adult-onset Still disease complicated by macrophage activation syndrome and toxic epidermal necrolysis.
Article in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 56-year-old woman with 1-year recurrent fever, rash, joint swelling (acute exacerbation) was diagnosed with adult-onset Still disease (AOSD) per 1992 Yamaguchi criteria. She initially improved with methylprednisolone, tocilizumab, methotrexate, and iguratimod but relapsed after discontinuing methylprednisolone. Twenty-four hours after first Re Du Ning injection, she developed progressive rash (extensive polymorphic erythema, bullae, and >30% body surface epidermal detachment), high fever, organ impairment, and coagulopathy and was diagnosed with AOSD complicated by macrophage activation syndrome (2004 haemophagocytic lymphohistiocytosis guidelines), toxic epidermal necrolysis, myocardial injury, hepatic impairment, and disseminated intravascular coagulation. Treatment included dexamethasone, methylprednisolone, plasma exchange, cyclosporine, anakinra, ganciclovir, voriconazole, intravenous immunoglobulin, and supportive care, leading to marked improvement in lesions. This case highlights rare AOSD complications and anakinra's efficacy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.